JP2012507994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012507994A5 JP2012507994A5 JP2011535101A JP2011535101A JP2012507994A5 JP 2012507994 A5 JP2012507994 A5 JP 2012507994A5 JP 2011535101 A JP2011535101 A JP 2011535101A JP 2011535101 A JP2011535101 A JP 2011535101A JP 2012507994 A5 JP2012507994 A5 JP 2012507994A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- hla
- fusion polypeptide
- antigen
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 230000004927 fusion Effects 0.000 claims 12
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims 6
- 108010024164 HLA-G Antigens Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims 1
- 101000986079 Homo sapiens HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 claims 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08168675A EP2184070A1 (en) | 2008-11-07 | 2008-11-07 | HLA-G proteins and pharmaceutical uses thereof |
| EP08168675.0 | 2008-11-07 | ||
| US11280408P | 2008-11-10 | 2008-11-10 | |
| US61/112,804 | 2008-11-10 | ||
| PCT/EP2009/064575 WO2010052228A1 (en) | 2008-11-07 | 2009-11-04 | Hla-g proteins and pharmaceutical uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012507994A JP2012507994A (ja) | 2012-04-05 |
| JP2012507994A5 true JP2012507994A5 (OSRAM) | 2012-12-06 |
Family
ID=40673439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535101A Pending JP2012507994A (ja) | 2008-11-07 | 2009-11-04 | Ｈｌａ−ｇタンパク質及びその薬学的使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110268737A1 (OSRAM) |
| EP (2) | EP2184070A1 (OSRAM) |
| JP (1) | JP2012507994A (OSRAM) |
| CA (1) | CA2742517A1 (OSRAM) |
| DK (1) | DK2352509T3 (OSRAM) |
| ES (1) | ES2423993T3 (OSRAM) |
| PT (1) | PT2352509E (OSRAM) |
| WO (1) | WO2010052228A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2443147A1 (en) * | 2009-06-18 | 2012-04-25 | Hla-G Technologies | Hla-g alpha 1 multimers and pharmaceutical uses thereof |
| WO2010150233A2 (en) | 2009-06-25 | 2010-12-29 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof |
| HUE041595T2 (hu) * | 2012-01-12 | 2019-05-28 | Bioverativ Therapeutics Inc | A VIII-as faktorral szembeni immunogenitás csökkentése a VIII-as faktorterápiát kapó egyéneknél |
| CA2876099A1 (en) | 2012-08-02 | 2014-02-06 | F. Hoffmann-La Roche Ag | Method for producing monomeric and multimeric molecules and uses thereof |
| BR112015013557B1 (pt) | 2012-12-11 | 2021-12-14 | Albert Einstein College Of Medicine | Sistema, método, método para determinar o efeito de um resíduo de aminoácido predeterminado de uma primeira proteína sobre a ligação da primeira proteína a uma segunda proteína e polipeptídeo pd-l1 mutante |
| CN106132428B (zh) * | 2014-01-21 | 2021-08-06 | 阿尔伯特爱因斯坦医学院 | 用于快速和全面t细胞免疫监测的细胞平台 |
| JP6416480B2 (ja) * | 2014-01-29 | 2018-10-31 | 国立大学法人北海道大学 | 関節リウマチまたはその関連疾患の予防または治療剤 |
| US9765330B1 (en) | 2015-01-09 | 2017-09-19 | Nant Holdings Ip, Llc | Compositions and methods for reduction of allograft recognition and rejection |
| CA3019005A1 (en) | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| AU2017266905B2 (en) | 2016-05-18 | 2022-12-15 | Albert Einstein College Of Medicine, Inc. | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof |
| JP7034950B2 (ja) | 2016-06-03 | 2022-03-14 | アンヴェクティ | 抗ｈｌａ－ｇ特異的抗体 |
| JP7519660B2 (ja) * | 2016-06-14 | 2024-07-22 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 疾患を処置するための遺伝子改変された細胞、組織、および臓器 |
| BR112019011198A2 (pt) | 2016-12-02 | 2019-12-17 | Bioverativ Therapeutics Inc | métodos de indução de tolerância imune a fatores de coagulação |
| JP7250677B2 (ja) | 2016-12-22 | 2023-04-03 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| KR102619015B1 (ko) | 2017-03-15 | 2023-12-28 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE |
| JP2021080171A (ja) * | 2018-03-13 | 2021-05-27 | 国立大学法人北海道大学 | 改変タンパク質、医薬品、炎症性疾患の予防又は治療剤及び改変タンパク質の製造方法 |
| CA3169949A1 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ， インコーポレイテッド | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2717498B1 (fr) | 1994-03-18 | 1996-05-03 | Commissariat Energie Atomique | Transcrits du gène de CMH de classe I HLA-G et leurs applications. |
| EP1054688B1 (fr) | 1998-02-20 | 2004-06-30 | Commissariat A L'energie Atomique | Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications |
| FR2794977B1 (fr) | 1999-06-18 | 2003-10-31 | Commissariat Energie Atomique | Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention |
| FR2810047B1 (fr) | 2000-06-13 | 2004-04-02 | Commissariat Energie Atomique | Nouvelle isoforme d'hla-g et ses applications |
| JP2008504008A (ja) * | 2003-12-31 | 2008-02-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質 |
| AU2005265071A1 (en) * | 2004-06-18 | 2006-01-26 | Memorial Sloan-Kettering Cancer Center | VEGF inhibitors for the treatment of malignant pleural effusion |
| WO2007011044A1 (ja) | 2005-07-15 | 2007-01-25 | Kyushu University, National University Corporation | ジスルフィド結合型hla-g二量体を含む医薬組成物及びジスルフィド結合型hla-g二量体の製造方法 |
| WO2007091078A2 (en) | 2006-02-10 | 2007-08-16 | Axordia Limited | Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g |
| WO2007133811A2 (en) * | 2006-05-15 | 2007-11-22 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
-
2008
- 2008-11-07 EP EP08168675A patent/EP2184070A1/en not_active Withdrawn
-
2009
- 2009-11-04 JP JP2011535101A patent/JP2012507994A/ja active Pending
- 2009-11-04 DK DK09747827.5T patent/DK2352509T3/da active
- 2009-11-04 CA CA2742517A patent/CA2742517A1/en not_active Abandoned
- 2009-11-04 WO PCT/EP2009/064575 patent/WO2010052228A1/en not_active Ceased
- 2009-11-04 ES ES09747827T patent/ES2423993T3/es active Active
- 2009-11-04 US US13/127,788 patent/US20110268737A1/en not_active Abandoned
- 2009-11-04 PT PT97478275T patent/PT2352509E/pt unknown
- 2009-11-04 EP EP09747827.5A patent/EP2352509B1/en not_active Not-in-force